Michel Ducreux and Teresa Macarulla discussing GI Cancer research on ESMO Daily Reporter

ESMO shared on LinkedIn:

“Whilst neoadjuvant chemotherapy is now a well-established strategy for treating some Gastrointestinal Tumours such as gastric, oesophageal and gastroesophageal cancers, for other digestive malignancies evidence from studies is promising although not yet practice changing.

Read the interview with Michel Ducreux and Teresa Macarulla discussing this hot topic in GI Cancer research on ESMO Daily Reporter.”

Source: ESMO/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up.

It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.